Молекулярные маркеры онкогенной активности вируса папилломы человека
Диссертация
Одним из важнейших достижений в области изучения рака является установление этиологической роли некоторых типов вируса папилломы человека (ВПЧ) в развитии рака шейки матки (РШМ). В настоящее время охарактеризовано более 80 типов ВПЧ и показано, что около 40 типов могут вызывать заболевания аногенитального тракта. На основании данных эпидемиологических и молекулярно-биологических исследований типы… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
- ГЛАВА 1. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Роль ВПЧ в этиологии рака шейки матки
- 1. 2. Профилактика рака шейки матки
- 1. 2. 1. Вакцинация
- 1. 2. 2. Скрининг женщин на рак шейки матки
- 1. 2. 2. 1. Классификация цервикальных цитологических поражений
- 1. 2. 2. 2. Скрининговые технологии
- 1. 3. Биология вируса папилломы человека
- 1. 3. 1. Классификация вируса папилломы человека
- 1. 3. 2. Жизненный цикл вируса папилломы человека
- 1. 3. 3. Организация генома вируса папилломы человека
- 1. 3. 4. Роль ранних белков вируса папилломы человека в онкогенной трансформации эпителиальных клеток
- 1. 3. 5. Молекулярные основы типоспецифических различий в трансформирующей активности вируса папилломы человека
- 1. 3. 6. Значение интеграции ДНК вируса папилломы человека в геном хозяина для онкогенной трансформации клеток
- 1. 4. Факторы риска цервикальной неопластической прогрессии, ассоциированные с вирусом папилломы человека
- 1. 4. 1. Инфицирование онкогенными типами и молекулярными вариантами вируса папилломы человека
- 1. 4. 2. Множественная папилломавирусная инфекция
- 1. 4. 3. Высокая вирусная нагрузка
- 1. 4. 4. Персистенция папилломавирусной инфекции
- 1. 4. 5. Нерегулируемая экспрессия вирусных онкогенов
- 2. 1. Схема исследования
- 2. 2. Клинический материал
- 23. Цитологические исследования!
- 2. 4. Выделение нуклеиновых кислот из клинического материала
- 2. 5. Полимеразная цепная реакция с типоспецифическими праймерами
- 2. 6. Приготовление компетентных клеток
- 2. 7. Выделение плазмиднойДНК
- 2. 8. Полимеразная цепная реакция в реальном времени
- 2. 9. Статистическая обработка данных
- 3. 1. Количес твенная полимеразная цепная реакция в реальном времени
- 3. 2. Методика определения физического статуса ДНК вирусов папилломы человека 16 и 18 типов
- 4. 1. Частота встречаемости онкогенных типов вируса папилломы человека при патологии шейки матки
- 4. 2. оцг.нка вирусной нагрузки у женщин с патологией шейки матки
- 4. 3. Физический статус ДНК вируса папилломьг человека при различных стадиях заболевания шейки матки
- 4. 4. типоспецифическая персистенция ВПЧ
Список литературы
- zur Hausen, Н. Human papilloma viruses and cancer / H. zur Hausen, L. Gissman, W. Steiner, et al. // Bibl Haematol. -1975. Vol.43. -P.596−571.
- Munoz, N. Epidemiologic classification of human papillomavirus types associated with cervical cancer / N. Munoz, F.X. Bosch, S. de Sanjose et al. // N Engl J Med. -2003. -P.348(6). -P.518−527.
- Syrjanen, К J. Biological behavior of cervical intraepithelial neoplasia / K.J. Syrjanen // New developments in cervical cancer screening and prevention.-Oxford: Blackwell Science, -1997. -P.93−108.
- Dalstein, V. Human papillomavirus testing for primary cervical cancer screening. / V. Dalstein, J. Bory, O. Graesslin, et al. // Emerging issues on HPV infections: from science to practice. Basel, Karger, 2006, pp 103−19.
- Dalstein, V. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study / V. Dalstein, D. Riethmuller, J.L. Pretet, et al. // Int J Cancer. -2003. -Vol.106.-P.396−403.
- Jeon, S. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells / S. Jeon, B, L. Allen-Hoffmann, P.F. Lambert // J Virol. -1995. -Vol.69. -P.2989−2997.
- Waggoner, S.E. Cervical cancer / S.E. Waggoner // Lancet. —2003. Vol.361.-P.2217−2225.
- Козаченко, В.П. Рак шейки матки / В. П. Козаченко // Современная онкология 2001. — Т.2. -№ 2. — С. 2−4.
- Коломиец, JI.A. Генитальная папиломавирусная инфекция и рак шейки матки. / JI.A. Коломиец, JI.H. Уразова Томск: Изд-во HTJI, 2002. — 100 с.
- Новик, В.И. Эпидемиология рака шейки матки, факторы риска, скрининг / В. И. Новик // Практическая онкология. 2002. — Т.З. — С. 156 165.
- Новикова, Е.Г. Органосохраняющее и функционально-щадящее лечение при раке шейке матки / Е. Г. Новикова, В. А. Антипов, Е. А. Ронина, О. И. Трушина // Вопросы онкологии. -2006. —Т. 52. № 1. — С. 78−82
- Чиссов, В.И. Злокачественные новообразования в России в 1998 г. (заболеваемость и смертность) / В.И. Чиссов- под ред. В. И. Чиссова, В. В. Старинского, JI.B. Ременник М.: МНИОИ им. П. А. Герцена, 2000. — 284 с.
- Jablonska, S. Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis / S. Jablonska, J. Dabrowski, K. Jakubowicz // Cancer Res. -1972. -Vol. 32. -P.583−589
- Bosch, F.X. The causal relation between human papillomavirus and cervical cancer / F.X. Bosch, A. Lorincz, N. Munoz, et al. // J Clin Pathol. -2002. -Vol.55. -P.244−265.
- Alazawi, W. Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16 / W. Alazawi, M. Pett, B. Arch, et al. // Cancer Res. -2002. -Vol.62. -P.6959−6965.
- Koutsky, L.A. A controlled trial of a human papillomavirus type 16 vaccine / L.A. Koutsky, K.A. Ault, C.M. Wheeler, et al. //N Engl J Med. -2002. Vol.347.-P. 1645−1651.
- Franco, E. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control / E. Franco, D.M. Harper // Vaccine. -2005. -Vol.23. -P.23 88−2394.
- Taira, A.V. Neukermans C.P., Sanders G.D. Evaluation human papillomavirus vaccination programs / A.V. Taira // Emerg Infect Dis. -2004. Vol.10.-P. 1915−1923.
- Уварова, Е.В. Репродуктивное здоровье девочек России в начале XXI века / Е. В. Уварова // Акушерство и гинекология. —2006. —№ 1.-С. 27−30.
- Манухин, И.Б. Заболевания наружных половых органов у женщин / И. Б. Манухин, Н. И. Кондриков, Т.П. Крапошина- М.: МИА, 2002. -303с.
- World Health Organization (WHO). Comprehensive Cervical Cancer Control. A guide to essential practice. Geneva: WHO 2006. URL: http://www.who.int/reproductive-health/publications/cervicalcancergep/text.pdf.
- Quinn, M. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics / M. Quinn, P. Babb, J. Jones, E. Allen // BMJ. -1999. -Vol.318. -P. 3.
- Sasieni, P. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model / P. Sasieni, J. Adams // BMJ. -1999. -Vol.318. -P.1244−1245.
- US Preventive Services Task Force. Screening for cervical cancer. Recommendations and rationale. AHRG Pub. No. 03−515A, January 2003. URL: http://www.ahrg.gov/clinic/3rduspstf/cervcan/cervcanrr.htm. Accessed 19 June 2006.
- The CancerWeb Project. URL: http ://cancerweb.ncl .ac.uk/cancernet/304 728.html.
- Sankaranarayanan, R. A critical assessment of screening methods for cervical neoplasia / R. Sankaranarayanan, L. Gaffikin, M. Jacob, et al. // Int J Gynecol Obstet. -2005. -Vol.89. -P.4−12.
- Solomon, D. The 2001 Bethesda System. Terminology for reporting results of cervical cytology / D. Solomon, D. Davey, R. Kurman, et al. // JAMA. -2002. -Vol.287. -№ 16. -P.2114−2118.
- Kocjan, G. BSCC, Bethesda or other? Terminology in cervical cytology European panel discussion / G. Kocjan, B.C. Priollet, M. Desair, et al. // Cytopathology. -2005. -Vol.16. -P.l 13−119.
- Nuovo, J. New tests for cervical cancer screening / J. Nuovo, J. Melnikow, L.P. Howell // Am Fam Physician. -2001. -Vol.64. -P.780−786.
- Karnon, J. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis / J. Karnon, J. Peters, J. Piatt // Health Technol Assess. -2004. -Vol.8. -№ 20.
- Saslow, D. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer / D. Saslow, C.D. Runowicz, B. Solomon, et al. // CA Cancer J Clin. -2002. -Vol.52. -P.342−362.
- Cancer Research UK. Cervical screening in the UK. URL: ht1p://info.cancen, esearchuk.org/cancerstats/types/cervix/screening.
- Wright, T.C. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening / T.C. Wright, M. Schiffinan, D. Solomon, et al. // Obstet Gynecol. -2004.-Vol. 103(2). -P.304−309.
- Molijn, A. Molecular diagnosis of human papillomavirus (HPV) infections / A. Molijn, B. Kleter, W. Quint, L.J. van Doom // J Clin Virol. -2005. -Vol.32. -Suppl.l:S43−51.
- Ault, K.A. Recommendations for the Diagnosis and Treatment of HPV Infections of Female Tract / K.A. Ault, K. Friese, L. Gissmann, et al. // European J for Infectious Diseases in Obstetrics and Gynecology. — 2002.
- European Cervical Cancer Screening Network. European guidelines for quality assurance in cervical screening. 2nd draft of 15 December 2003. URL: http://www.cancer-network.de/
- IARC WHO Press Release 151 IARC confirms efficacy of cervix cancer screening for women 25−65 in reducing mortality, 03 May 2004
- Monsonego, J. Cervical Cancer Control Priorities and new directions / J. Monsonego, F.X. Bosch, P. Coursaget, et al. // Int J Cancer. -2004. -Vol.108. -P.329−333.
- Monsonego, J. EUROGIN 2006 expert consensus report Innovations in cervical cancer prevention: Science, practice and actions / J. Monsonego // Gynecol Oncol. -2006 Aug 9-
- Wright, T.C. 2001 consensus guidelines for the management of women with cervical cytological abnormalities / T.C. Wright, J.T. Cox, L.S. Massad, et al. //JAMA. -2002. -Vol.287. -P.2120−2129.
- ACOG: ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Cervical cytology screening (replaces committee opinion 152, March 1995) / Obstet Gynecol. 2003. — Vol. 102. — № 45. -P. 417−427.
- Cuzick, J. Management of women who test positive for high-risk types of human papillomavirus: the HART study / J. Cuzick, A. Szarewski, H. Cubie, et al. // Lancet. -2003. -Vol.362. -P.1871−1876.
- Cuzick, J. New dimensions in cervical cancer screening / J. Cuzick, M.H. Mayarand, G. Ronco, et al. // Vaccine. -2006. -Vol.24. -Supl.3. -P.90−97
- Petry, U.A. German project uses HPV-testing as primary screening test in the prevention of cervical cancer / U.A. Petry // HPV Today. —2006. — Vol.9. —P.7.
- Clavel, C. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions / C. Clavel, J. Cucherousset, M. Lorenzato et al. // Br J Cancer. -2004. -Vol.90. -№ 9. -P. 1803−1808.
- Munoz, N. Against which human papillomavirus types shall we vaccinate and screen? The international perspective / N. Munoz, F.X. Bosch, X. Castellsague, et al. // Int J Cancer. -2004. -Vol. 111. -P.278−285.
- Goldie, S J. Cost-effectiveness of Cervical-cancer Screening in Five Developing Countries / S J. Goldie, L. Gafficin, J.D. Goldhaber-Fiebert, et al. // N Engl J Med. -2005. -Vol.353(20). -P.2158−2168.
- Bernard, H.U. Evolution of papillomaviruses / H.U. Bernard, S.-Y. Chan, H. Delius // Cur Top Microbiol Immunol. -1994. -Vol.186. -P.33−53.
- Syijanen, K. Epidemiology of human papillomavirus infection and genital neoplasia / K. Syrjanen, S. Syijanen // Scand J Infect Dis Suppl. -1990. -Vol.69. -P.7−17.68. zur Hausen, H. Viruses and Cancer / H. zur Hausen // Cambridge. — 1985. P.83−90.
- Doorbar, J. Molecular biology of human papillomavirus infection and cervical cancer / J. Doorbar // Clin Sei (Lond). —2006. -Vol. 110(5). -P.525−541.
- Борисов JI.Б. Медицинская микробиология, вирусология, иммуногия / Л. Б. Борисов, A.M. Смирнова —М.: Изд-во Медицина, 1994. — 528 с.
- Козлова В.И. Вирусные, хламидийные и микоплазменные заболевания гениталий / В. И. Козлова, А. Ф. Пухнер -М.: Изд-во Филин, 1997.-536 с. 72. zur Hausen, Н., Gissman, L. Viral Oncology / H. zur Hausen, L. Gissman- Ed. G. Klein.-New York, 1980. -P.433.
- Калинин, В.Л. Введение в молекулярную вирусологию / В. Л. Калинин // СПб.: СПбГТУ, 2002. 302 с.
- Nishimura, A. Mechanism of human papillomavirus E2-mediated repression of viral oncogene expression and cervical cancer cell growthinhibition / A. Nishimura, T. Ono, A. Ishimoto, et al. // J Virol -2000. -Vol.74. -P.3752−3760.
- Киселев, Ф.Л. Клонирование трансформированных генов вирусов папилломы человека типа 18 / Ф. Л. Киселев // Вопросы вирусологии. -1997.-№ 6. С. 248−251.
- Nagao, S. Rapid and sensitive detection of physical status of human papillomavirus type 16 DNA by quantitative real-time PCR / S. Nagao, M. Yoshinouchi, Y. Miyagi, et al. // J Clin Microbiol. -2002. -Vol.40. -P.863−867.
- Jeon, S. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis / S. Jeon, P.F. Lambert // Proc Natl Acad Sci USA. — 1995. -Vol.92. -P.1654−1658.
- Хансон, К.П. Современные представления о канцерогенезе рака шейки матки / К. П. Хансон, Е. Н. Имянитов // Практическая онкология. -2002. -Т.З. -С.145−155.
- Francis, D.A. Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells / D.A. Francis, S.I. Schmid, P.M. Howley // J Virol. -2000. -Vol.74. -P.2679−2686.
- Munger, K. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein / K. Munger, J.R. Basile, S. Duensing, et al. // Oncogene. -2001. -Vol.20. -P.7888−7898.
- Luo, R.X. Rb interacts with histone deacetylase to repress transcription / R.X. Luo, A.A. Postigo, D.C. Dean // Cell. -1998. —Vol.92. -P.463−473.
- Weintraub, S.J. Retinoblastoma protein switches the E2 °F site from positive to negative element / S.J. Weintraub, C.A. Prater, D.C. Dean // Nature. -1992. -Vol.358. —P.259−261.
- Weintraub, S.J. Mechanism of active transcriptional repression by the retinoblastoma protein / S.J. Weintraub, K.N. Chow, R.X. Luo, et al. // Nature. -1995. -Vol.375. -P.812−815.
- Smotkin, D. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein / D. Smotkin, F.O. Wettstein // Proc Natl Acad Sci USA. -1986. -Vol.83. -P.4680−4684.
- Barbosa, M.S. Papillomavirus polypeptides E6 and E7 are zinc-binding proteins / M.S. Barbosa, D.R. Lowy, J.T. Schiller // J Virol. -1989. -Vol.63.-P. 1404−1407.
- Lee, J.O. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7 / J.O. Lee, A.A. Russo, N.P. Pavletich // Nature. -1998. -Vol.391. -P.859−865.
- Dyson, N. The regulation of E2 °F by pRB-family proteins / N. Dyson // Genes Dev. -1998. -Vol.12. -P.2245−2262.
- Flores, E.R. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle / E.R. Flores, B.L. Allen-Hoffmann, D. Lee, P.F. Lambert // J Virol. -2000. -Vol.74. -P.6622−6631.
- Funk, J.O. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein / J.O. Funk, S. Waga, J.B. Harry, et al. // Genes Dev. -1997. -Vol.11. -P.2090−2100.
- Nurnberg, W. Nuclear proto-oncogene products transactivate the human papillomavirus type 16 promoter / W. Nurnberg, M. Artuc, G. Vorbrueggen, et. al. // Br J Cancer. -1995. -Vol.71. -P.l 018−1024.
- Scheffner, M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 / M. Scheffner, J.M. Huibregtse, R.D. Vierstra, P.M. Howley // Cell. -1993. -Vol.75. -P.495−505.
- Bechtold, V. Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA / V. Bechtold, P. Beard, K. Raj // J Virol. -2003. -Vol.77. -P.2021−2028.
- Stunkel, W. Nuclear matrix attachment regions of human papillomavirus type 16 repress or activate the E6 promoter, depending on the physical state of the viral DNA / W. Stunkel, Z. Huang, S.H. Tan, et al. // J Virol. -2000. -Vol.74. -P.2489−2501.
- Romanczuk, H. Disruption of either the El or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity / H. Romanczuk, P.M. Howley // Proc Natl Acad Sci USA. -1992. -Vol.89. -P.3159−3163.
- Hou, S.Y. Transcriptional activity among high and low risk human papillomavirus E2 protein correlates with E2 DNA binding / S.Y. Hou, S.Y. Wu, C.M. Chiang // J Biol Chem. -2002. -Vol.277. -P.45 619−45 629.
- Thorland, E.C. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors / E.C. Thorland, S.L. Myers, B.S. Gostout, D.I. Smith // Oncogene. -2003. -Vol.22. -P. 1225−3127.
- Mullokandov, M.R. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status / M.R. Mullokandov, N.G. Kholodilov, N.B. Atkin, et al. // Cancer Res. -1996. -Vol.56.-P. 197−202.
- Goldie, SJ. Analysis of intratumoral heterogeneity of chromosome 3p deletions and genetic evidence of polyclonal origin of cervical squamous carcinoma / SJ. Goldie, F. Wu, A. Asplund, et al. // Mod Pathol. -2001. -Vol.14.-P.54−61.
- Mazurenko, N. High resolution mapping of chromosome 6 deletions in cervical cancer / N. Mazurenko, M. Attaleb, T. Gritsko, et al. // Oncol Reports. -1999. -Vol.6. -P.859−863.
- Koopman, L.A. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer / L.A. Koopman, W.E. Corver, A.R. van der Slik, et al. // J. Exp. Med. -2000. -Vol.191. -P.961−975.
- Xi, L.F. Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection / L.F. Xi, W. Demers, L.A. Koutsky et al. // J Infect Dis. -1995. -Vol.172. -P.747−755.
- Ong, C.K. Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect co-evolution with human ethnic groups / C.K. Ong, S.-Y. Chan, M.S. Campo, et al. // J Virol -1993. -Vol.67. -P.6424−6431.
- Heinzel, P.A. Variation of human papillomavirus type 6 (HPV-6) and HPV-11 genome samples throughout the world / P.A. Heinzel, S.-Y. Chan, L. Ho, et al. // J Clin Microbiol. -1995. -Vol.33. -P. 1746−1754.
- Ho, L. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations / L. Ho, S.-Y. Chan, R.D. Burk, et al. // J Virol. —1993. — Vol.67. -P.6413−6423.
- Xi, L.F. Genomic variation of human papillomavirus type 16 and risk for high-grade cervical intraepithelial neoplasia / L.F. Xi, L.A. Koutsky, D.A. Galloway, et al. // J Nation Cancer Inst. -1997. -Vol.89. -P.796−802.
- Villa, L.L. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia / L.L. Villa, L. Sichero, P. Rahal, et al. // J Gen Virol. -2000. -Vol.81. -P.2959−2968.
- Londesborough, P. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities / P. Londesborough, L. Ho, G. Terry, et al. // Int J Cancer. -1996. -Vol.69.-P.364−368.
- Song, Y.S. Major sequence variants in E7 gene of human papillomavirus type 16 from cervical cancerous and non-cancerous lesions of Korean women / Y.S. Song, S.H. Kee, J.W. Kim, et al. // Gynaecol Oncol. -1997. -Vol.66. -P.275−281.
- Franco, E. Molecular variant analysis as an epidemiological tool to study persistence of cervical human papillomavirus infection / E. Franco, L.L. Villa, P. Rahal, A. Ruiz // J Nation. Cancer Inst. -1994. -Vol.86. -P.1558−1559.
- Junes, K.S. Intratypic variability of HPV-16 and -18 in tumour biopsies from a high risk area for cervical cancer / K.S. Junes, L. Sichero, W. Mello, et al. // 18th International Papillomavirus Conference. -2000, 23−28 July. -Barcelona, Spain.
- Zehbe, I. The biological significance of human papillomavirus type 16 variants for the development of cervical neoplasia /1. Zehbe, M. Tommasino // Papillomavirus Report. -1999. -Vol.10. -P.105−116.
- Swan, D.C. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type / D.C. Swan, R.A. Tucker, G., Tortolero-Luna, et al. // J Clin Microbiol. -1999. -Vol.37. -P.1030−1034.
- Perovic, M.V. High-risk human papillomavirus (HPV) types in patients with squamous intraepithelial lesions (SIL) / M.V. Perovic, M.J.
- Berisavac, N. Kuljic-Kapulica, T. Jovanovic // Eur J Gynaecol Oncol. —2003. — Vol.24. -P.178−180.
- Fife, K.H. Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia / Fife K.H., Cramer H.M., Schroeder J.M., Brown D.R. // J Med Virol. -2001. -Vol.64. -P.550−559.
- Szoke, K. Moderate variation of the oncogenic potential among high-risk human papillomavirus types in gynecologic patients with cervical abnormalities / K. Szoke, T. Sapy, Z. Krasznai, et al. // J Med Virol-2003. -Vol.71. -P.585−592.
- Bekkers, R.L. Effects of HPV detection in population-based screening programmes for cervical cancer- a Dutch moment / R.L. Bekkers, C J. Meijer, L.F. Massuger, et al. // Gynecol Oncol. -2006. -Vol. 100. -№ 3 -P.451−452.
- Peto, J. The cervical cancer epidemic that screening has prevented in the UK / J. Peto, C. Gilham, O. Fletcher, F.E. Matthews // Lancet. -2004. -Vol. 364. —P.249−256.
- Ho, G.Y. Natural history of cervicovaginal papillomavirus infection in young women / G.Y. Ho, R. Bierman, L. Beardsley, et al. // N Engl J Med. -1998. -Vol.338. -P.423−428.
- Moscicki. A.B. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women / A.B. Moscicki, S. Shiboski, J. Broering, et al. // J Pediatr. -1998. -Vol.132. -P.277−284.
- Samoylova. E.V. HPV infection in cervical-cancer cases in Russia / E.V. Samoylova, G.O. Shaikhaiev, S.V. Petrov, et al. // Int J Cancer. -1995. -Vol.61.-P.337−341.
- Vernon, S.D. Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer / S.D. Vernon, E.R. Unger, D.L. Miller, et al. // Int J Cancer. -1997. -Vol.74. -P.50−56.
- Киселев, Ф.Л. Статус ДНК вируса папиллом человека в опухолях шейки матки / Ф. Л. Киселев, Н. П. Киселева, В. К. Кобзева и др. // Мол. Биол. Клетки. -2001. -Т.35. С. 470−476.
- Gallo, G. Study of viral integration of HPV-16 in young patients with LSIL / G. Gallo, M. Bibbo, L. Bagella, et al. // J Clin Pathol. -2003. -Vol.56. -P.532−536.
- Kraus, I. Human papillomavirus oncogenic expression in the displastic portio- an investigation of biopsies from 190 cervical cones /1. Kraus, Т. Molden, L.E. Erno, et al. // Brit J Cancer. -2004. -Vol.90. -P. 1407−1413.
- Cuschieri, K.S. Human papillomavirus type specific DNA and RNA persistence implications for cervical disease progression and monitoring / K.S. Cuschieri, M.J. Whitley, A.C. Heather // J. Med. Virol. -2004. -Vol.73. -P.65−70.
- Evans, M.F. Human papillomavirus integration: detection by in situ hybridization and potential clinical application / M.F. Evans, K. Cooper // J Pathol. -2004. -Vol.202. -P. 1−4.
- Boom, R. Rapid and simple method for the purification of nucleic acids / R. Boom, C.J.A. Sol, M.M. Salimans, C.L. Hansen, et al. // J Clin Microbiol. -1990. -Vol.28. -P.495−503.
- Inoue, H. High efficiency transformation of with Escherichia coli Plasmids / H. Inoue, H. Nojima, H. Okayama // Gene. -1990. -Vol.96. -P.23−28.
- Lee, S.Y. A simple procedure for maximum yield of high-quality Plasmid DNA / S.Y. Lee, A. Rasheed // Biotechniques. -1990. -Vol.9. -P.676−679.
- Лагутин, М.Б. Наглядная математическая статистика: Учебное пособие / М. Б. Лагутин. — М.: БИНОМ. Лаборатория знаний, 2007.^72 с.
- Herrington, C.S. Human papillomavirus and cervical neoplasia. Classification, virology, pathology, and epidemiology / C.S. Herrington // J Clin Pathol. -1994. -Vol.47. -P.1066−1072.
- Cuschieri, K.S. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population / K.S. Cuschieri, H.A. Cubie, M.W. Whitley, et al. // J Clin Pathol. -2004. -Vol.57. -P.68−72.
- Thomas, K.K. Concurrent and sequential acquisition of different genital human papillomavirus types / K.K. Thomas, J.P. Hughes, J.M. Kuypers et al. // J Infect Dis. -2000. -Vol.l82. -P. 1097−1102.
- Rolon, P.A. Human papillomavirus infection and invasive cervical cancer in Paraguay / P.A. Rolon, J.S. Smith, N. Munoz, et al. // Int J Cancer. -2000. —Vol.85. -P.486−491.
- Rousseau, M.C. Predictors of cervical coinfection with multiple human papillomavirus types / M.C. Rousseau, M. Abrahamowicz, L.L. Villa, et al. // Cancer Epidemiol. Biomarkers Prev. -2003. -Vol.12. -P.1029−1037.
- Lee, S.A. Multiple HPV infection in cervical cancer screened by HPV DNA Chip / S.A. Lee, D. Kang, S.S. Seo, et al. // Cancer Lett. -2003. -Vol.198. -P.187−192.
- Cuzick, J. Role of HPV testing in clinical practice / J. Cuzick // Virus Res. -2002. -Vol.89. -P.263−269.
- Lorincz, A.T. Screening for cervical cancer: new alternatives and research / A.T. Lorincz // Salud Publica Мех. 2003. — Vol.45. — Suppl.3. -P.376−387.
- Ostor, A.G. Natural history of cervical intraepithelial neoplasia — a critical review / A.G. Ostor // Int J Gynecol Pathol. -1993. -Vol.12. -P.186−192.
- Cuzick, J. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia / J. Cuzick, G. Terry, L. Ho, et al. // Br J Cancer. -1994. -Vol.69. -P.167−171.
- Mansell, M.E. Semi-quantitative human papillomavirus DNA detection in the management of women with minor cytological abnormality / M.E. Mansell, L. Ho, G. Terry, et al. // Br J Obstet Gynaecol.-1994. -Vol. 101.-P.807−809.
- Snijders, J.F.S. The Value of Viral Load in HPV Detection in Screening / J.F.S. Snijders, C.J.L.M. Meijer // HPV Today. -2006. -Vol.8. -P.8−9.
- Moberg, M. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma / M. Moberg, I. Gustavsson, E. Wilander, U. Gyllensten // Br J Cancer. -2005. -Vol.92. -891−894.
- Moberg, M. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ / M. Moberg, I. Gustavsson, U. Gyllensten // Int J Cancer. -2004. -Vol.112(5). -P.854−859.
- Duensing, S. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins / S. Duensing, K. Munger // Int J Cancer. -2004. -Vol. 109. -P. 157−162.
- Pepe, M.S. Phases of biomarker development for early detection of cancer / M.S. Pepe, R. Etzioni, Z. Feng, et al. // J Natl Cancer Inst. -2001. -Vol.93.-P.1054−1061.
- Baldwin, P. Translation approaches to improving cervical screening / P. Baldwin, R. Laskey, N. Coleman // Nat Rev Cancer. 2003. -№ 3. -P.217−226.
- Murphy, N. pl6INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer / N. Murphy, M. Ring, C.C. Heffron, et al. // J Clin Pathol. -2005. -Vol.58. -P.525−534.
- Steenbergen, R. HPV-mediated transformation of the anogenital tract / R. Steenbergen, J. de Wilde, S. Wilting, et al. // J Clin Virol. -2005. -Vol.32. -Suppl.S25−33.
- Lehn, H.L. Physical state and biological activity of human papillomavirus genomes in precancerous lesions of the female genital tract / H.L. Lehn, L.L. Villa, F. Marziona, et al. // J Gen Virol. -1998. -Vol.69. -P. 187−196.
- Cullen, A.P. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasms / A.P. Cullen, R. Reid, M. Campion, A.T. Lorincs // J Virol. -1991. -Vol.65. -P.606−612.
- Pirami, L. Analysis of HPV16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix // L. Pirami, V. Giache, A. Becciolini // J Clin Pathol. -1997. -Vol.50. -P.600−604.i • / '
- Badaracco, G. HPV16 and HPV18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness / G. Badaracco, A. Venuti, A. Sedati, M.L. Marcante // J Med Virol. -2002. -Vol.67. -P.574−582.